Global White Biotechnology Market

Biotechnology services refer to the services that modify living microorganisms to provide biotechnology products on a contract or custom basis to medical, pharmaceutical, and scientific laboratories. They provide breakthrough products and technologies to combat debilitating and rare diseases, reduce our environmental footprint, feed the hungry, use less and cleaner energy, and have safer, cleaner and more efficient industrial manufacturing processes. The main types of biotechnology services are prevention and disease control; public engagement activities; health education and research; food biotechnology services; donor recruitment; tissue collection; cell processing and isolation; and research and development. Food biotechnology services encompass a diverse variety of technologies used in crops, livestock, forestry, fisheries and aquaculture, and agro-industry. They are used for a variety of purposes, including genetic improvement of plants and animals to increase yields or efficiency, characterization and conservation of genetic resources for food and agriculture, plant and animal disease diagnosis, vaccine development, and fermented food production. The various applications include pharmaceutical, biotechnological, academic, clinical trial, and healthcare sectors and are used by Clinical Research Organizations (CROs), Contract Manufacturers Organizations (CMOs), and Contract Research and Manufacturing Services (CRAMS). The biotechnology services market research report is one of a series of new reports from The Business Research Company that provides biotechnology services market statistics, including biotechnology services industry global market size, regional shares, competitors with a biotechnology services market share, detailed biotechnology services market segments, market trends and opportunities, and any further data you may need to thrive in the biotechnology services industry. This biotechnology services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global biotechnology services market size will grow from $146.85 billion in 2022 to $163.71 billion in 2023 at a compound annual growth rate (CAGR) of 11.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global biotechnology services market size is expected to grow to $241.17 billion in 2027 at a CAGR of 10.2%. The increasing pervasiveness of conditions like hepatitis B, diabetes, and cancer is driving research in biotechnology. Biotechnology uses research tools from biology and chemistry to study the genetic material of bacteria and viruses to check the disease-producing agents. Oncology research is most prominent among biopharma companies. Stem cell treatment using a monoclonal antibody for therapy and genome sequencing is progressing in medical applications. According to the Indian Economic Survey 2021, the Indian biotechnology business is predicted to grow to US$ 150 billion by 2025. Global R&D spending by the world's largest publicly traded biotech companies increased by 13.7 percent each year, from $4.8 billion in 2001 to $55.0 billion in 2020. Therefore, the rising pervasiveness of diseases and huge expenses on R&D are predicted to contribute to the growth of the biotechnology services market. The risk related to genetic data is anticipated to limit the growth of the biotechnology services market. The biotechnological approach of transferring specially created genes for modification in characteristics to create genetically modified organisms (GMOs) has always been considered a threat to human and environmental health. According to the report of the World Conservation Union, there are numerous environmental risks likely to occur due to the use of GMOs, which include interbreeding, antibiotic resistance, impact on the ecosystem, creation of new or worse viruses, competition with natural species, unpredictable and unintended effects, and ethical concerns. The World Health Organization (WHO) has also set guidelines for manufacturers of GMO food. The National Bioengineered Food Disclosure Standard has been implemented in the USA since January 2020, making it mandatory to label all foods containing genetically engineered items as "bioengineered". Thus, the risk associated with genetically modified items is negatively impacting the growth of the biotechnology services market. Collaborations and partnerships between industry players are a growing trend in the field of biotech services. In January 2021, Novartis, a Switzerland-based pharmaceutical company collaborated with Alnylam, a US-based biopharmaceutical company for exploration in the application of the latter’s siRNA technology and the development of targeted therapy for the restoration of liver function. As part of the exclusive three-year research collaboration, Alnylam will develop and test potential siRNAs using Novartis' target-specific assays. Novartis will conduct further development and clinical research once a lead candidate has been identified. In October 2021, Amgen, a US-based biopharmaceutical company, acquired all outstanding shares of Teneobio for a deal amount of $2.5 billion. Amgen acquired Teneobio's bispecific and multispecific antibody technologies as part of the acquisition. These solutions complement the company's existing antibody expertise and BiTE platform. This will aid in the discovery and advancement of novel molecules for the treatment of a wide range of illnesses in Amgen's major treatment areas. TeneoBio is a US-based biotechnology business that specialises in the production of human heavy chain antibodies. Major players in the biotechnology services market are Novartis, Fisher BioService, Pfizer, Novo Nordisk, BioAlps, Precision for Medicine, Sartorius and Aldevron. Asia-Pacific was the largest region in the biotechnology services market in 2022. North America was the second largest region in the global biotechnology services market. The regions covered in the global biotechnology services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the biotechnology services market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The biotechnology services market consists of revenue earned by entities that engage in conducting research and experimental development in biotechnology. Numerous global issues are helped by biotechnology, including infectious diseases, ageing societies, food security, energy security, and climate change, to name a few. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products. The global biotechnology services market is segmented - 1) By Service: Prevention and Disease Control, Public Engagement Activities, Health Education and Research, Food Biotechnology Services, Donor Recruitment, Tissue Collection, Cell Processing and Isolation, Research and Development 2) By Industry: Clinical Research Organizations (CROs), Contract Manufacturers Organizations(CMOs), Contract Research and Manufacturing Services (CRAMS) 3) By Area of Application: Pharmaceutical, Biotechnological, Academic, Clinical Trial, Healthcare Sectors

The scientific research and development services are responsible for conducting original research on a systematic basis to gain new knowledge and to apply research findings or other scientific knowledge to create new or improved products or processes. The main types of scientific research and development services are social sciences and humanities services; physical, engineering, and life sciences; nanotechnology services; and biotechnology services. Nanotechnology is the near-atomic manipulation of matter to create new structures, materials, and technologies. Many fields, including medical, consumer goods, energy, materials, and manufacturing, will benefit from the technology. The different sizes of enterprises include large enterprises, small and medium enterprises, and involve various modes such as online and offline. The scientific research and development services market research report is one of a series of new reports from The Business Research Company that provides scientific research and development services market statistics, including scientific research and development services industry global market size, regional shares, competitors with a scientific research and development services market share, detailed scientific research and development services market segments, market trends and opportunities, and any further data you may need to thrive in the scientific research and development services industry. This scientific research and development services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global scientific research and development services market grew from $817.06 billion in 2022 to $897.68 billion in 2023 at a compound annual growth rate (CAGR) of 9.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, and affecting many markets across the globe. The scientific research and development service market is expected to grow from $1,254.27 billion in 2027 at a CAGR of 8.7%. The scientific research and development services market is expected to grow rapidly due to increasing lifestyle and chronic diseases. This is mainly due to unhealthy lifestyles, a growing ageing population, rising inactivity and obesity. According to the World Health Organization, chronic disease prevalence reached 57% globally in 2020. China and India together had about 193.4 million diabetic patients in 2019, and India is expected to have about 101 million diabetic patients by 2030. In the field of mental health, the World Health Organization predicts that one in every four people will be affected by a type of mental disorder such as depression, schizophrenia, or anxiety in the future. In response to this, national governments across the globe are rapidly increasing their medical research expenditure. For instance, China's medical research spending has increased and will reach $1 trillion in 2020. Therefore, increasing investment in medical research to treat chronic diseases is further driving the demand for scientific research and development services. The outbreak of COVID-19 disease (COVID-19) has acted as a restraint on the scientific research and development services market in 2020 as governments globally imposed lockdowns and restricted trade, thereby limiting the need for professional services. COVID-19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People’s Republic of China and has spread globally, including Western Europe, North America, and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of "lock down." The outbreak has had a negative impact on businesses throughout 2020 and into 2021. However, it is expected that the scientific research and development services market will recover from the shock over the forecast period as it is a "black swan" event and not related to ongoing or fundamental weaknesses in the market or the global economy. 4D printing has evolved from 3D printing with the additional feature of changing the geometrical shape and mechanical properties, with time being integrated as an additional fourth dimension. One of the major drawbacks of 3D printing is that it can only take the shape in which it was originally made and is static and inanimate. With the latest development of 4D printing, objects can now be made with responsive materials with certain inherent properties that can change or transform in response to external stimuli. It has widespread applications in medical science, such as tissue regeneration in the biomedical field. For example, printed micro tissue from bio ink can undergo maturation via cellular coating to form functional tissue constructs such as engineered tissue constructs. Major biotechnology research companies using 4D bio printing technology include Poietis, Biolife4D, and Precise Bio. Major companies in the scientific research and development services market include IQVIA Holdings Inc., Battelle Memorial Institute, Defense Advanced Research Projects Agency, Lawrence Livermore National Laboratory LLC, Charles River Laboratories, Inc., Frog Design, Lawrence Berkeley National Lab, Jackson Laboratory, Piramal Group, and WuXi AppTec Co., Ltd. North America was the largest region in the scientific research and development services market in 2022. Asia-Pacific was the second largest region in the scientific research and development services market. The regions covered in the scientific research and development services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the scientific research and development services market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The scientific research and development services market consists of revenue earned by entities that engage in research and experimental development on a contract, consultancy, or outsourced basis. Scientific research and development services establishments undertake processes where human capital is the major input. They make available the knowledge and skills of their employees, often on an assignment basis, where an individual or team is responsible for the delivery of services to the client. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global scientific research and development services market is segmented - 1) By Type: Social Sciences And Humanities Services, Physical, Engineering, And Life Sciences, Nanotechnology Services, Biotechnology Services 2) By End User Size: Large Enterprise, Small and Medium Enterprise 3) By Mode: Online, Offline

Research antibodies and reagents refer to the antibodies that bioscientists utilise as basic detection techniques. These are used to designate and distinguish particular proteins that are found within the sick cell at a particular stage of its life cycle. The main types of technologies in research antibodies and reagents are western blot, immunofluorescence, immunohistochemistry, flow cytometry, enzyme-linked immunosorbent assay (ELISA), multiplex immunosorbent assay, immunoprecipitation, and others. The western blot, also known as western blotting, is molecular biology and immunogenetics analytical technique for detecting specific proteins in a sample of tissue homogenate or extract. The different applications include proteomics, drug discovery & development, and genomics and are implemented in various sectors such as the pharmaceutical & biotechnology industry, academic & research institutes, and contract research organizations (CROs). The research antibodies and reagents market research report is one of a series of new reports from The Business Research Company that provides research antibodies and reagents market statistics, including research antibodies and reagents industry global market size, regional shares, competitors with a research antibodies and reagents market share, detailed research antibodies and reagents market segments, market trends and opportunities, and any further data you may need to thrive in the research antibodies and reagents industry. This research antibodies and reagents market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global research antibodies and reagents market grew from $13.19 billion in 2022 to $14.02 billion in 2023 at a compound annual growth rate (CAGR) of 6.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The research antibodies and reagents market is expected to grow from $18.85 billion in 2027 at a CAGR of 7.7%. Increasing investment in medical and health research and development (R&D) is predicted to contribute to the growth of the research antibodies and reagents market. In the field of life science research, antibodies and reagents are essential components for the investigation of biological processes or causes of diseases through careful experimentation, observation, laboratory work, analysis, and testing. For instance, in April 2021, according to a report published by the Congressional Budget Office, a US-based government agency that provides budget and economic information, pharmaceutical companies will have invested $83 billion on research and development activities around the world. According to the Assobiotec publication BioInItaly 2020, healthcare is involved in 49% of the over 700 biotech firms headquartered in Italy. Thus, increasing investment in healthcare research and development will increase the utilization of the research antibody and reagent market. Reproducibility issues of antibodies and reagents are expected to hamper the growth of the research antibodies and reagents market. Reproducibility is the ability of an experiment or calculation to be duplicated by other researchers working independently. The prevalence of irreproducible preclinical research exceeded 50%, resulting in approximately $28 billion spent on preclinical research every year. Among the irreproducible research, the largest fraction of about 36% is assigned to biological reagents, which amounts to $10 billion annually. This huge research waste is due to insufficiently validated antibodies and irreproducible reagents that are not appropriate for the target proteins. Thus, reproducibility issues with antibodies and reagents are expected to restrain market growth. Technological advancements in the area of purification of antibodies and reagents show opportunities for the growth of the research antibodies and reagents market during the forecast period. Irreproducible antibodies and reagents are a major challenge for the industry, as this will affect the outcome of the research. For instance, in July 2020, Sysmex Corporation, a Japan based diagnostic tools manufacturing company, launched antibody measurement technology for the Coronavirus (SARS-CoV-2) Antibody Lab Assay Service and Antibody Measurement Reagents. These tools were employed in a clinical performance assessment that involved IgG antibody detection. They were utilized to compare IgG antibody concentrations in relation to circulating N and S antigens between SARS-CoV-2 patients and a group of SARS-CoV-2 patients after leaving the hospital. In February 2022, Rockland Immunochemicals, Inc., a US-based company that specializes in the development of assays and basic research tools using antibodies, acquired Antibodies-Online GmbH for an undisclosed amount. Through this acquisition, Rockland, utilizing the reputable e-commerce brand, extensive supplier network, and proprietary technology stack of antibodies-online, achieves excellence in the design, development, and manufacture of antibodies and assays. Customers of each business will have access to improved capabilities supported by richer and more comprehensive data sets, enhancing their overall customer experience and boosting their go-to-market strategy. Antibodies-Online GmbH is a Germany based company that provides antibodies, reagents, and research kits to companies. Major players in the research antibodies and reagents market are Becton Dickinson and Company, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, PerkinElmer Inc., Lonza Group AG, Abcam PLC., GenScript Biotech Corporation, and Bio-Techne Corporation. North America was the largest region in the research antibodies and reagents market in 2022. The regions covered in the global research antibodies and reagents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the research antibodies and reagents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The research antibodies and reagents market consists of sales of buffers, fixatives, solvents, and enzymes. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global research antibodies and reagents market is segmented - 1) By Technology: Western Blot, Immunofluorescence, Immunohistochemistry, Flow Cytometry, Enzyme-linked Immunosorbent Assay (ELISA), Multiplex Immunosorbent Assay, Immunoprecipitation, Other Technologies 2) By Application: Proteomics, Drug Discovery & Development, Genomics 3) By End-User: Pharmaceutical & Biotechnology Industry, Academic & Research Institutes, Contract Research Organizations (CROs)

Contract development manufacturing organizations refer to businesses that work on a contract basis with the pharmaceutical sector to provide medication development and manufacturing services. These businesses enable the pharmaceutical industry to outsource some of its operations, freeing up crucial time to concentrate on medication development and marketing. The contract development manufacturing organizations are segmented by service into CMO, CRO; by product into small molecules, biologics and by end user into big pharma, small and mid-size pharma, generic pharmaceutical companies, and other end users. The contract development manufacturing organizations market research report is one of a series of new reports from The Business Research Company that provides contract development manufacturing organizations market statistics, including contract development manufacturing organizations industry global market size, regional shares, competitors with a contract development manufacturing organizations market share, detailed contract development manufacturing organizations market segments, market trends and opportunities, and any further data you may need to thrive in the contract development manufacturing organizations industry. This contract development manufacturing organizations market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global contract development manufacturing organizations market size grew from $196.26 billion in 2022 to $218.64 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The contract development manufacturing organizations market size is expected to grow to $339.72 billion in 2027 at a CAGR of 11.6%. The growing demand for pharmaceutical products due to the increase in chronic diseases and the geriatric population contributed to the growth of the contract development manufacturing organizations market. Rising chronic diseases and geriatric population has enabled pharmaceutical companies to manufacture biologics and biosimilars quickly, and most pharmaceutical firms have contracted contract production and manufacturing organizations operating on a contractual basis to handle and coordinate the company's tasks, operations and tests. For instance, according to the World Health Organization, the prevalence of chronic diseases rose by 57% in 2020 and by 2050 the world's population of 60 years and older is projected to rise to 2 billion. Therefore, the growing demand for pharmaceutical products is projected to drive the growth of the contract development manufacturing organizations market. Stringent government regulations in the drug approval process may restrict the growth of the contract development manufacturing organizations market. Several governments across the globe are enforcing controls on pharmaceutical firms to safeguard the population from adverse drug effects. These regulations further delay the process of introducing innovative pharmaceuticals onto the marketplace. For instance, on average, it requires at least ten years for a new drug to finish the process from the early creation to the marketplace, with clinical studies itself lasting six to seven years on average. According to data from PhRMA in 2020, the average chance of clinical success (the possibility that a drug undergoing clinical trials will finally be accepted) is calculated to be less than 12%. Therefore, the stringent government regulations are projected to impede the growth of the contract development manufacturing organizations market over the coming years. The introduction of custom solutions is a key trend gaining popularity in the market for contract development and manufacturing organizations. Contract development and manufacturing companies focus on the implementation of custom technologies to address the unique needs of individual research applications. For instance, in October 2022, Aenova Holding GmbH, a Germany based pharmaceutical and healthcare contract manufacturing company, entered into a strategic partnership with Microcaps, a Switzerland based pharmaceutical company. Through this collaboration, both companies can develop and produce medicines, food supplements, and many other things more quickly and better. Microcaps will share their knowledge of cutting-edge, highly accurate microencapsulation and Utilizing a patented technological platform, the technique allows for customized formulations, such as in release, protective coating, and texture. In February 2022, Recipharm AB, a Sweden based pharmaceutical contract development and manufacturing company, acquired Arranta Bio for an undisclosed amount. Through this acquisition, Recipharm forms the basis of a plan to offer contract development and manufacturing services that are scientifically unique to innovative drug developers in the biologics industry, increases its capabilities in new biologics modalities, and will deliver a high level of diversification across many technologies and modalities. Arranta Bio is a US-based contract development and manufacturing organization (CDMO) that collaborates with businesses looking to develop and produce novel medicines and complicated biological pharmaceuticals. Major players in the contract development manufacturing organizations market are Recipharm AB., Patheon Inc., Boehringer Ingelheim International, Catalent Inc., Lonza Group Ltd., Thermo Fisher Scientific Inc., Aenova Holding, Almac Group, Vetter, and Covance Inc., North America was the largest region in contract development manufacturing organizations market in 2022. The regions covered in the contract development manufacturing organizations market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the contract development manufacturing organizations market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The contract development manufacturing organizations market includes revenues earned by entities by formulation, analytical services, blending, coating, and converting. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global contract development manufacturing organizations market is segmented - 1) By Service: CMO, CRO 2) By Product: Small Molecules, Biologics 3) By End User: Big Pharma, Small and Mid-size Pharma, Generic Pharmaceutical Companies, Other End Users

Pharmaceutical contract development and manufacturing refers to a business that offers services for drug research and manufacture within the pharmaceutical sector. Using CDMOs as a partner, pharmaceutical companies can outsource medication development and production. Full-service drug development and manufacturing outsourcing companies (CDMOs) can handle every stage of the process and work with clients that want to outsource specific steps in their workflow. Everything is based on the requirements of each client. The main types of pharmaceutical contract development and manufacturing organisations (CMO) are active pharmaceutical ingredient (API) manufacturing, finished dosage formulation (FDF) development and manufacturing, and secondary packaging. The active pharmaceutical ingredient (API) manufacturing includes the manufacturing of the part of any drug that produces the desired effects. The various research phases include preclinical, phase I, phase II, phase III, and phase IV. The different end-use sectors include big pharmaceutical companies, generic pharmaceutical companies, and small & medium-sized pharmaceutical companies. The pharmaceutical contract development and manufacturing market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical contract development and manufacturing market statistics, including pharmaceutical contract development and manufacturing industry global market size, regional shares, competitors' pharmaceutical contract development and manufacturing market share, detailed pharmaceutical contract development and manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical contract development and manufacturing industry. This pharmaceutical contract development and manufacturing market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global pharmaceutical contract development and manufacturing market grew from $122.31 billion in 2022 to $130.82 billion in 2023 at a compound annual growth rate (CAGR) of 7.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pharmaceutical contract development and manufacturing market is expected to grow from $196.53 billion in 2027 at a CAGR of 10.7%. The growth of the pharmaceutical contract development and manufacturing market is driven by the increase in the demand for medicines across the globe. The high prevalence of diseases and the need for a longer lifespan increased the demand for medicines pushing the pharmaceutical companies to increase the production of existing drugs and raise the investment in their R&D to promote the development of new drugs. This impels the pharmaceutical companies to collaborate with contract manufacturing organizations (CMOs) as a way to lower operational costs, thus, increasing the demand for pharmaceutical contract development and manufacturing market. According to Alkermes PLC., a biopharmaceutical company indicates that pharmaceutical contract manufacturing will emerge as a strategic option for many companies ranging from very large to smaller specialty pharma entities and this mostly will happen because the pharmaceuticals companies are looking for cost-cutting. The pharmaceutical contract development and manufacturing market are restricted by the poor-capacity utilization of manufacturing facilities. The capacity utilization is calculated considering the full potential capacity of the production plant. The poor-capacity utilization of the production plant is caused due to the inefficiency of different sub-processes in the production line which results in low production. The low production output results in low revenue generation for the production unit, affecting the overall pharmaceutical contract development and manufacturing market. For instance, in January 2020, according to an article shared by Economic Times, an India-based English-language business-focused daily newspaper, The 1,500 API manufacturing facilities in India, according to the country's drug regulatory organisation, are only operating at 40% of their potential. Therefore, the usage of capacity of the production plant negatively affects the pharmaceutical contract development and manufacturing market. The companies in the pharmaceutical contract development and manufacturing market are investing in acquiring and forming alliances with other companies in the market. The pharmaceutical contract development and manufacturing companies are following the trend of merger and acquisition to expand their global market reach to meet the client needs, increase their production capabilities while maintaining cost efficiencies, and get access to the latest technology and new services. The high levels of merger and acquisition activities are resulting in the consolidation of the contract service providers. For instance, in July 2022, Pharma Nobis, a US-based provider of contract manufacturing and private label services, acquired Fagron’s U.S. contract manufacturing business for an undisclosed amount. Through this acquisition, Pharma Nobis is expected to offer contract manufacturing and private label services to American retailers and consumer healthcare corporations. 20% of the company will continue to be owned by Fagron. In August 2022, Catalent, Inc., a US-based provider of delivery technologies, development, and drug manufacturing, acquired Metrics Contract Services for $475 million. This acquisition is expected to improve Catalent's ability to work with highly potent chemicals while enhancing its expertise in integrated oral solid formulation research, production, and packaging to assist clients in streamlining and accelerating their processes. Metrics Contract Services is a US-based pharmaceutical contract development and manufacturing organization. Major players in the pharmaceutical contract development and manufacturing market are Recipharm AB, Pfizer Inc., Boehringer Ingelheim International GmbH, Aenova Group, Famar, Jubilant Life Sciences Limited, Catalent Pharma Solutions, Chemicals Limited, Dishman Pharmaceuticals, HAUPT Pharma AG, Kemwell Pvt. Ltd., Nipro Corp., NextPharma, Royal DSM N.V., Althea Technologies, Thermo Fisher Scientific Inc., Lonza Group Ltd., AbbVie Inc., Consort Medical PLC., Almac Group, Siegfried Holding AG, Evonik Industries AG, and Vetter Pharma International GMBH. North America was the largest region in the global pharmaceutical contract development and manufacturing market in 2022. The Middle East is expected to be the fastest growing region in the global pharmaceutical contract development and manufacturing market during the forecast period. The regions covered in the global pharmaceutical contract development and manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the pharmaceutical contract development and manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The pharmaceutical contract development and manufacturing market includes revenues earned by entities by providing drug development and manufacturing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global pharmaceutical contract development and manufacturing organisation (CMO) market is segmented - 1) By Type: Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development and Manufacturing, Secondary Packaging 2) By Research Phase: Preclinical, Phase I, Phase II, Phase III, Phase IV 3) By End-User: Big Pharmaceutical Companies, Generic Pharmaceutical Companies, Small & Medium-Sized Pharmaceutical Companies

Services refer to transactions between a buyer and a seller without transferring any physical goods or commodities, involving the use of resources, experience, skill, ingenuity, and intelligence. It mainly involves the use of resources, experience, skill, ingenuity, and intelligence. The main types of services include Civic Services, Real Estate, Leasing, Commercial Services, Personal Services, and Repair and Maintenance. Civic service is defined as a structured period of significant engagement and commitment to the local, national, or international community that is acknowledged and recognized by society, with little or no monetary recompense to the individual. The components including hardware, software, and service. The different modes include online and offline. The services market research report is one of a series of new reports from The Business Research Company that provides services market statistics, including services industry global market size, regional shares, competitors with a services market share, detailed services market segments, market trends, and opportunities, and any further data you may need to thrive in the services industry. This services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global services market grew from $13,978.41 billion in 2022 to $15,223.84 billion in 2023 at a compound annual growth rate (CAGR) of 8.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The services market is expected to grow to $20,650.56 billion in 2027 at a CAGR of 7.9%. Rapid advances in technology are expected to drive innovation in different sectors of the services industry, thus driving the market during the forecast period. Areas of rapid technological change included electronic equipment, automobiles, and electronics, which in turn will lead to an increase in services for that equipment. Furthermore, technologies such as 3D printing, artificial intelligence, and big data analytics are increasingly being used, resulting in higher productivity, lower operating costs, and higher margins. Lower operating costs lead to higher margins, this allows companies to increase product portfolio and enter new markets by making investments made through cost savings. IoT applications are also being integrated into services to enable services such as remote monitoring, and central feedback systems, and to offer other services. These factors are expected to drive the services market going forward. The outbreak of COVID-19 disease (COVID-19) has acted as a massive restraint on the services market in 2020 as the need for services offered by these establishments declined due to lockdowns imposed by governments globally. COVID-19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty in breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People's Republic of China, and spread globally including Western Europe, North America, and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of 'lockdown' and the outbreak had a negative impact on businesses throughout 2020 and into 2021. However, it is expected that the services market will recover from the shock across the forecast period as it is a 'black swan event and not related to ongoing or fundamental weaknesses in the market or the global economy. With companies focusing on core business operations, automated billing systems are widely being used to minimize billing errors and reduce costs. Automated systems generate and send electronic copies of invoices directly to customers. Automated billing systems can result in savings of 60-80% compared to traditional paper-based billing systems. Automated billing systems also enable tracking of unpaid bills, automating payment reminders and recurring invoices, managing discounts, and coupons, and creating of customized invoices. These systems also generate real-time reports on sales, orders, and budgets that help track business performance. Some of the popular automated billing systems include Zoho Invoice, QuickBooks, Invoice2go, and Intacct. Major companies in the services market include BCD Travel, Enterprise Holdings Inc., Randstad Holding NV, Adecco Group, Travel Leaders Group, TUI Group, Recruit Holdings, ManpowerGroup Inc., Berkshire Hathaway Inc., and Waste Management Inc. Asia-Pacific was the largest region in the services market in 2022. North America was the second-largest region in the services market. The regions covered in the services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the services market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, Vietnam. The services market consists of revenue earned by entities by providing services to equipment and machinery repairing, promoting or administering religious activities, grant making, advocacy, and providing dry-cleaning and laundry services, personal care services, death care services, pet care services, photofinishing services, and temporary parking services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global services market is segmented - 1) By Type: Civic Services, Real Estate, Leasing, Commercial Services, Personal Services, Repair and Maintenance 2) By Component: Hardware, Software, Service 2) By Mode: Online, Offline Subsegments Covered: Religious Organizations, NGOs And Charitable Organizations, Political Organizations, Unions And Associations, Real Estate Rental, Real Estate Agency and Brokerage, Automotive Equipment Leasing, Consumer Goods And General Rental Centers, Machinery Leasing, Lessors Of Nonfinancial Intangible Assets, Office Administrative Services, Facilities Support Services, Employment Services, Business Support Services, Travel Arrangement And Reservation Services, Waste Management And Remediation Services, Investigation And Security Services, Services to Buildings And Dwellings, Other Support Services,, Personal Care Services, Death Care Services, Dry-Cleaning And Laundry Services, Other Personal Services, Private Household Services, Automotive Repair and Maintenance, Commercial and Industrial Machinery and Equipment Repair and Maintenance, Electronic and Precision Equipment Repair and Maintenance, Personal Goods Repair And Maintenance

Biotechnology reagents refer to chemical compounds that are used in detecting, measuring, and preparing a product, and others by facilitating chemical. Biotechnology reagents are used in the quantification and detection of desired substances, as the binding of reagents to the substance or other related substances triggers certain reactions. The main types of biotechnology reagents are life science reagents, analytical reagents, and other reagents. Life science reagents refer to the substances used in a chemical reaction to observe the data record changes and to analyze this data to determine the cause of a disease. It is used in various applications such as protein synthesis and purification, gene expression, DNA and RNA analysis, and drug testing. The various end-users include biotech companies, research institutes, pharmaceuticals, diagnostic centers, academic institutes, and other end-users. The biotechnology reagents market research report is one of a series of new reports from The Business Research Company that provides Biotechnology reagents market statistics, including Biotechnology reagents industry global market size, regional shares, competitors with a Biotechnology reagents market share, detailed Biotechnology reagents market segments, market trends and opportunities, and any further data you may need to thrive in the Biotechnology reagents industry. This Biotechnology reagents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global biotechnology reagents market size is expected to grow from $72.01 billion in 2022 to $78.47 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The biotechnology reagents market size is expected to grow to $110.93 billion in 2027 at a CAGR of 9.0%. The rising demand for polymerase chain reaction (PCR) is expected to propel the growth of the biotechnology reagents market going forward. Polymerase chain reaction (PCR) refers to the molecular technique that is used to amplify smaller segments of DNA into large segments used to diagnose certain infectious diseases and study genetic changes. For polymerase chain reaction (PCR), biotechnology reagents are used to maintain a stable pH during the PCR process to ensure proper DNA synthesis function, which can later be used for various genomic studies and diagnosis purposes. For instance, in July 2021, Weqaya UAE, a UAE-based national agency for awareness and reassurance under the supervision of the National Crisis & Emergency, conducted more than 60 million RT-PCR tests across the emirates due to its capabilities in detecting infections in a shorter period of time. The UAE's health officials increased the number of tests per day from an average of 10,000 by the end of March 2020 to 120,000 in November and more than 270,000 in July 2021 as part of measures to combat the pandemic. Therefore, the rising demand for polymerase chain reaction (PCR) is driving the growth of the biotechnology reagents market. Technological advancement is the key trend that is gaining popularity in the biotechnology reagent market. Major companies are focused on developing innovative products based on new technologies to strengthen their position in the biotechnology reagent market. For instance, in April 2022, CN BIO Innovations, a UK-based company operating in single and multi-organ micro-physiological systems and innovative lab technologies, introduced the PhysioMimix in-a-box reagent kit for non-alcoholic steatohepatitis (NASH) and severe non-alcoholic fatty liver disease (NAFLD) that can be used in an Organs-on-Chip system to provide researchers with in-house capabilities to study mechanics and physiological responses of disease concerning drug efficacy and safety toxicology, which facilitates more accurate and cost-effective drug development. In April 2022, Meridian Bioscience, a US-based life science company that develops, manufactures, and distributes purified reagents and related products, acquired Euprotein Inc for an undisclosed amount. This acquisition is expected to help Meridian increase its recombinant capabilities while accelerating its pipeline of novel immunological tools. Euprotein is a US-based biotechnology company that offers specialized development and manufacturing of bioresearch reagents. Major players in the biotechnology reagents market are Life Technologies Corporation, Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Water Corporation, Sigma-Aldrich, Agilent Technologies Inc., Becton Dickinson and Company, Beckman Coulter Inc., Roche Holding AG, Abbott Laboratories, General Electric incorporated, PerkinElmer Inc., Merck Group, bioMérieux SA, Siemens Healthineers AG, Lonza Group, Hoefer Inc., Quality Biological Inc., Tosoh Corporation, Promega Corporation, Bio-Techne Corporation, Takara Bio Inc., and Sysmex Corporation. North America was the largest region in the biotechnology reagents market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biotechnology reagents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the biotechnology reagents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and the USA. The biotechnology reagents market includes revenues earned by entities by chromatography, in-vitro diagnostics, polymerase chain reaction and cell culture technologies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global biotechnology reagents market is segmented - 1) By Type: Life Science Reagents, Analytical Reagents,Other Reagents 2) By Applications: Protein synthesis and purification, Gene expression, DNA and RNA analysis, Drug testing 3) By End-Users: Biotech companies, Research institutes, Pharmaceuticals, Diagnostic centers, Academic Institute, Other End-Users

Animal biotechnology refers to the use of science and engineering techniques by which living organisms are modified to benefit humans and other animals. Animal biotechnology is used to modify the genome of animals, known as genetic engineering, to improve their suitability in pharmaceuticals, industrial, and agriculture applications. The main type of product of animal biotechnology include diagnostics tests, vaccines, drugs, reproductive and genetic and feed additives that are animals such as companion and livestock. Diagnostics tests refer to a set of techniques that are used to diagnose a disease or condition of organisms. Animal biotechnology is applied in diagnosis of animal diseases, treatment of animal diseases, preventive care of animals, drug development and other applications  and used in laboratories, point-of-care testing/in-house testing, veterinary hospitals & clinics and other end-use. The animal biotechnology market research report is one of a series of new reports from The Business Research Company that provides animal biotechnology market statistics, including animal biotechnology industry global market size, regional shares, competitors with an Critical infrastructure protection market share, detailed animal biotechnology market segments, market trends and opportunities, and any further data you may need to thrive in the animal biotechnology industry. This animal biotechnology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global animal biotechnology market size is expected to grow from $25.53 billion in 2022 to $27.67 billion in 2023 at a compound annual growth rate (CAGR) of 8.40%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The animal biotechnology market size is expected to reach $38.32 billion in 2027 at a CAGR of 8.48%. The growing awareness regarding animal health and welfare is expected to propel the animal biotechnology market going forward. Animal health and welfare are concerned with how people interact with animals and their responsibility to ensure that the animals in their care are handled appropriately and compassionately. In animal health and welfare, animal biotechnology helps in improving animal productivity via increasing growth, reproduction quality, nutrition, feed utilization, food safety, and others for more efficient utilization of resources. For instance, according to American Pet Products Association (APPA), a US-based trade association in the pet industry, approximately $123.6 billion was spent on pet products by United States citizens in 2021 and products include supplies, OTC medicine, veterinary care, and others. Additionally, in July 2021, the Department of Animal Husbandry and Dairying, the India-based official department for livestock, allocated a budget of INR 54,618 crores ($106.83 million) for the development of animal husbandry and dairying across the country for the next 5 years. The schemes include livestock health and disease control, the national program for dairy development, national livestock mission, and others. Therefore, the growing awareness regarding animal health and welfare is driving the growth of the animal biotechnology market. Product innovation is a key trend in the animal biotechnology market. Major market players are focusing their efforts on developing novel goods like virus-like particle (VLP) technology for vaccine development.  For instance, in April 2022, Cadila Pharmaceuticals, an India-based multinational pharmaceutical company, introduced a three-dose rabies vaccine prepared using virus-like particle technology for rabies known as ThRabis®. Virus-like particles (VLPs) refer to a vaccine-developing technique that uses multiprotein structures to mimic the form and size of a virus particle but lacks the viral genome that potentially yields safer and cheaper vaccine candidates. ThRabis® consists of recombinant nanoparticle-based rabies G protein that generates antibodies against rabies G protein that neutralize the virus and impedes virus attachment to the cell to achieve protection against rabies. In January 2020, Heska Corporation, a US-based company operating in veterinary and animal health diagnostic products acquired Scil animal care company GmbH for $125 million. Through this acquisition, Heska corporation aims to strengthen its product portfolio in animal biotechnology and its position in veterinary point of care laboratory and imaging diagnostics. Scil animal care company GmbH is an US-based company operating in animal biotechnology. Major players in the animal biotechnology market are Zoetis Inc., Boehringer Ingelheim International GmbH, Biogenesis Bago SA, Merck & Co., Inc., Virbac, Elanco Animal Health Incorporated, IDEXX Laboratories Inc., Heska Corporation, Bayer AG, Pfizer Inc., Sanofi SA, Santa Cruz Biotechnology Inc., Indian Immunologicals Limited, Hester Biosciences Limited, Intervet Inc., Idvet, Abbott Laboratories, Genus PLC, Ivaoes Animal Health, and Novartis AG. North America was the largest region in the animal biotechnology market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the animal biotechnology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the Animal Biotechnology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and the USA. The animal biotechnology market includes revenues earned by entities by using animal biotechnology for dogs, cats, horses, poultry, swine, cattle, sheep, goats and fish. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.  The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global animal biotechnology market is segmented - 1) By Product Type: Diagnostics Tests, Vaccines, Drugs, Reproductive And Genetic, Feed Additives 2) By Animal Type: Companion, Livestock 3) By Application: Diagnosis Of Animal Diseases, Treatment Of Animal Diseases, Preventive Care Of Animals, Drug Development, Other Applications 4) By End-Use: Laboratories, Point-Of-Care Testing/In-house Testing, Veterinary Hospitals And Clinics, Other End-Uses